Reference | Switzerland | EPICure | Epipage | Norway | Australia | Canadian NICUs | EPIBel | Sweden | Providence | Ulm | |
Overall | CTC Range | ||||||||||
23 | 24 | 27 | 29 | 26 | 25 | 28 | 37 | 32 | |||
Time period | 2000–4 | 2000–4 | 1995 | 1995 | 1999–2000 | 1998–2002 | 1996–7 | 1999–2000 | 1992–8 | 1993–7 | 1996–9 |
Study population | pb | pb | pb | pb | pb | pb | pb | hb | hb | hb | |
mc | mc | mc | mc | mc | mc | mc | mc | sc | sc | ||
ib/ob | ib/ob | ib/ob | ib/ob | ib/ob | ib only | ib only | ib only | ib only | ib only | ||
Total population | |||||||||||
Live births, n | 516 | 1185 | 207 | 178 | 843 | 797 | 175 | 213 | 211 | 96 | |
Survivors, n | 180 | 314 | 72 | 99 | 313 | 338 | 70 | 140 | 127 | 74 | |
Survivors, % | 35% | 16–53% | 26% | 35% | 56% | 37% | 42% | 40% | 66% | 60% | 77% |
22 weeks | |||||||||||
Live births, n | 18 | 138 | 16 | 8 | 144 | 103 | 2 | NA | 22 | 4 | |
Survivors, n | 0 | 2 | 0 | 0 | 0 | 1 | 0 | NA | 1 | 1 | |
Survivors, % | 0% | 0% | 1% | 0% | 0% | 0% | 1% | 0% | NA | 5% | 25% |
23 weeks | |||||||||||
Live births, n | 82 | 241 | 30 | 35 | 144 | 150 | 18 | 40 | 41 | 13 | |
Survivors, n | 4 | 26 | 0 | 9 | 23 | 25 | 1 | 17 | 19 | 9 | |
Survivors, % | 5% | 0–20% | 11% | 0% | 26% | 16% | 17% | 6% | 43% | 46% | 69% |
24 weeks | |||||||||||
Live births, n | 158 | 382 | 42 | 64 | 264 | 242 | 65 | 70 | 61 | 31 | |
Survivors, n | 47 | 100 | 13 | 35 | 111 | 107 | 19 | 44 | 36 | 23 | |
Survivors, % | 30% | 0–53% | 26% | 31% | 55% | 42% | 44% | 29% | 63% | 59% | 74% |
25 weeks | |||||||||||
Live births, n | 258 | 424 | 119 | 71 | 291 | 302 | 90 | 103 | 87 | 48 | |
Survivors, n | 129 | 186 | 59 | 55 | 179 | 205 | 50 | 79 | 71 | 41 | |
Survivors, % | 50% | 38–74% | 44% | 50% | 77% | 62% | 68% | 56% | 77% | 82% | 85% |
CTC, centre-to-centre; hb, hospital-based; ib, inborn; mc, multicentre; ob, outborn; pb, population-based; sc, single centre.